preview watch
rest us pharma larg cap earn
stretch larg cap earn fairli activ
earn cycl us pharma
struggl result see boost
share like help lower bar peer set
note present updat model follow review latest
prescript price data two larger-cap compani
yet report feb teva feb expect solid quarter
compani least in-lin ep focu
guidanc teva present first time
updat loxo deal disappoint lartruvo data maintain
rate target price compani head earn
initi guidanc behind us chang come soon
beat rush provid initi guidanc releas
back dec howev import develop sinc
includ acquisit loxo announc
suspend promot lartruvo product fail show
overal surviv benefit confirmatori announc trial current
factset consensu non-gaap ep appear
fulli updat two event base assess appear
true consensu closer one look model
updat sinc mid-januari non-gaap ep
adjust model two event also ahead
quarter look earn call see develop
impact lli guidanc well updat lli plan
divest remain share still own
focu teva shift growth driver restructur like
track quit remark much teva stori chang
stabil ceo kore schultz leadership job
bare year comfort around on-going restructur program
look see teva growth driver perform includ ajovi
austedo brand side well gener epipen
compani reportedli difficulti suppli first-tim guidanc
cours scrutin assess outlook well
see compani truli return top line growth
previous suggest ep roughli line
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
figur usd strengthen vs major currenc basket sinc oct neg impact top
reflect guidanc us major pharma compani announc result date
yoy chang trade weight dollar index major currenc index
board governor feder reserv system us trade weight dollar index major currenc good dtwexm retriev fred feder reserv bank st
trade weight major currenc index base exchang rate us dollar basket major currenc includ euro area canada japan unit kingdom
switzerland australia sweden
charl martineau univers toronto figur fx rate end januari fx headwind us major estim
pronounc soften toward
yoy chang trade weight dollar index major currenc index
chang
figur sequenti usd expect modestli weaker
qoq chang trade weight dollar index major currenc index
chang
watch
ep consensu beat rush provid
initi guidanc releas back dec howev
import develop sinc includ acquisit
loxo announc suspend promot lartruvo
product fail show overal surviv benefit confirmatori
announc trial current factset consensu non-gaap ep
appear fulli updat two event base
assess appear true consensu closer one
look model updat sinc mid-januari non-
gaap ep adjust model
two event also ahead quarter make chang
ep revis ep look
earn call see develop impact lli
guidanc well updat lli plan divest remain
share still own
notabl model updat rais estim humulin
humalog trulic lower basaglar trulic humalog
like higher consensu lower lartruvo
sale ep assum lartruvo sale model
incorpor loxo deal dilut earli year
offset accret pipelin later year lead chang
target price pharma anim health
earn look commentari updat fy
guidanc initi uptak emgal competit migrain market
commerci dynam key growth driver trulic jardianc
verzenio taltz olumi lli thought hh propos
rule rebates/saf harbor might impact lli busi
valuat metric
number share
price month
 close
co discov develop manufactur sell
pharmaceut product human anim manufactur
distribut product facil us puerto rico
countri
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
trulic jardianc taltz galcanezumab olumi verzenio
lartruvo compar current base case assumpt also
model higher gross margin oper margin base
case assumpt blue sky valuat base dcf driven
wacc termin valu assign lilli
share elanco per share
grey sky valuat base lower sale trulic
jardianc taltz galcanezumab olumi verzenio lartruvo
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
assign lilli share elanco per share
 close
figur cs estim metric
watch
consensu ep consensu quit
remark much teva stori chang stabil
ceo kore schultz leadership job bare year
comfort around on-going restructur program look see
teva growth driver perform includ ajovi austedo
brand side well gener epipen compani reportedli
difficulti suppli first-tim guidanc cours
scrutin assess outlook well see compani
truli return top line growth previous suggest
ep roughli line consensu
notabl model updat increas forecast copaxon
higher consensu vs consensu
rais larg off-set conserv forecast gener
lower consensu vs bn consensu model
elidel ajovi could prove
conserv revis ep
risk includ better-/worse-than expect execut
restructur debt pay product launch execut
earn look commentari detail
compani initi fy guidanc progress date compani
broad ambiti restructur program updat commerci
uptak key growth driver ajovi austedo statu
portfolio priorit effort gener busi
valuat metric
number share
price month
 close
teva israel-bas pharmaceut compani focus primarili
research develop commerci gener
specialti drug two oper segment gener medicin
specialti medicin
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat driven larg part effici
optim gener busi slower anticip
eros copaxon sale launch new product
compani debt situat resolv effici
grey sky valuat driven larg part bearish
assumpt around sale copaxon gener
busi us need renogoti debt
 close
figur cs estim teva metric
sale
total incom expens
provis incom tax
sale
incom invest
incom incom tax
share loss associ compani net
net incom non-control interest
net gain loss attribut non-control interest
dividend prefer share
weight average share use calcul dilut ep
charl martineau univers toronto compani mention price
